Guy Faust

1.6k total citations · 1 hit paper
30 papers, 1.0k citations indexed

About

Guy Faust is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Guy Faust has authored 30 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in Guy Faust's work include Bladder and Urothelial Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Renal cell carcinoma treatment (6 papers). Guy Faust is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Renal cell carcinoma treatment (6 papers). Guy Faust collaborates with scholars based in United Kingdom, United States and Spain. Guy Faust's co-authors include David J. Boocock, William P. Steward, Andreas J. Gescher, James A. Crowell, Ketan Patel, Tristan D. Booth, Dean E. Brenner, Victoria Brown, Murray P. Ducharme and Marjorie Perloff and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Guy Faust

27 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent

2007 675 citations David J. Boocock, Guy Faust et al. Cancer Epidemiology Biomarkers & Prevention profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guy Faust United Kingdom	8	568	341	242	194	128	30	1.0k
Edwina N. Scott United Kingdom	10	270 0.5×	430 1.3×	281 1.2×	128 0.7×	69 0.5×	12	956
Manuel Gonzálvez Spain	9	406 0.7×	256 0.8×	51 0.2×	264 1.4×	182 1.4×	13	1.0k
Na‐Young Song South Korea	22	134 0.2×	711 2.1×	238 1.0×	119 0.6×	149 1.2×	59	1.4k
Grygoriy Vasilinin United States	3	324 0.6×	194 0.6×	77 0.3×	139 0.7×	80 0.6×	9	565
Chiara De Santi Italy	19	199 0.4×	349 1.0×	81 0.3×	77 0.4×	55 0.4×	38	870
Sumit Singh Verma India	14	140 0.2×	541 1.6×	113 0.5×	85 0.4×	77 0.6×	24	1.0k
Si Gao China	15	147 0.3×	536 1.6×	112 0.5×	80 0.4×	179 1.4×	23	1.1k
Mi‐Hua Liu China	20	131 0.2×	403 1.2×	87 0.4×	140 0.7×	188 1.5×	31	1.0k
L. Giovannini Italy	11	304 0.5×	189 0.6×	48 0.2×	134 0.7×	45 0.4×	34	647

Countries citing papers authored by Guy Faust

Since Specialization

Citations

This map shows the geographic impact of Guy Faust's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Faust with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Faust more than expected).

Fields of papers citing papers by Guy Faust

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Faust. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Faust. The network helps show where Guy Faust may publish in the future.

Co-authorship network of co-authors of Guy Faust

This figure shows the co-authorship network connecting the top 25 collaborators of Guy Faust. A scholar is included among the top collaborators of Guy Faust based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy Faust. Guy Faust is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Babu, Shyamaladevi, et al.. (2025). Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study. Current Oncology. 32(3). 168–168.

Albigès, Laurence, Hans J. Hammers, Walter M. Stadler, et al.. (2025). KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 43(5_suppl). 552–552. 1 indexed citations

Morgan, Bruno, et al.. (2023). NICE 2022 guidelines on the management of melanoma: Update and implications. Journal of Plastic Reconstructive & Aesthetic Surgery. 85. 401–413. 2 indexed citations

Márquez‐Rodas, Iván, Luigi Formisano, Sophie Papa, et al.. (2022). Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. JMIR Cancer. 8(2). e35930–e35930. 5 indexed citations

Faust, Guy, et al.. (2022). The Experiences of Patients With Adjuvant and Metastatic Melanoma Using Disease-Specific Social Media Communities in the Advent of Novel Therapies (Excite Project): Social Media Listening Study. JMIR Cancer. 8(2). e34073–e34073. 6 indexed citations

Sagkriotis, Alexandros, Iván Márquez‐Rodas, Luigi Formisano, et al.. (2022). POSA357 Social Media Listening for Melanoma Care Across European Markets. Value in Health. 25(1). S219–S219. 1 indexed citations

Crabb, Simon J., Syed A. Hussain, Samantha Hinsley, et al.. (2022). A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.. Journal of Clinical Oncology. 40(6_suppl). 436–436. 17 indexed citations

Corrie, Pippa, Sarah J. Welsh, Grant D. Stewart, et al.. (2021). Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study.. Journal of Clinical Oncology. 39(15_suppl). TPS2665–TPS2665. 1 indexed citations

Zhang, Shuai, Laura Spiers, Ali Abdulnabi Suwaidan, et al.. (2020). Impact of age on the toxicity of immune checkpoint inhibition. Journal for ImmunoTherapy of Cancer. 8(2). e000871–e000871. 62 indexed citations

10.

Uccello, Mario, et al.. (2019). Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution. Clinical Genitourinary Cancer. 17(3). e658–e663. 1 indexed citations

11.

Suwaidan, Ali Abdulnabi, et al.. (2018). Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma. BMJ Case Reports. 2018. bcr–2018. 15 indexed citations

12.

Zhang, Shuai, Laura Spiers, Zayd Tippu, et al.. (2018). The impact of patient age on toxicity and efficacy of immunotherapy agents.. Journal of Clinical Oncology. 36(15_suppl). e15116–e15116. 2 indexed citations

13.

Suwaidan, Ali Abdulnabi, et al.. (2018). The efficacy and safety of rechallenge with an alternative immune checkpoint inhibitor in metastatic malignant melanoma. Annals of Oncology. 29. x19–x20. 3 indexed citations

14.

Faust, Guy, et al.. (2018). Phenotyping Metastatic Brain Tumors Applying Spectrochemical Analyses: Segregation of Different Cancer Types. Analytical Letters. 52(4). 575–587. 15 indexed citations

15.

Hussain, Syed A., Jawaher Ansari, Robert Huddart, et al.. (2017). VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. International Journal of Oncology. 50(3). 768–772. 6 indexed citations

16.

Hussain, Syed A., Jawaher Ansari, Robert Huddart, et al.. (2015). VICTOR: Vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)—A retrospective analysis of use of Vin in multicenter, real life setting as second-line chemotherapy (ChT) through free-of charge-programme (FOCP) for patients (pts) in the UK.. Journal of Clinical Oncology. 33(7_suppl). 352–352. 3 indexed citations

17.

Jackson, Rod, Jawaher Ansari, Robert Huddart, et al.. (2015). 2632 VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): A retrospective analysis of the use of Vinflunine in a multi-centre real life setting as second line chemotherapy through the free of charge programme (FOCP) for patients in the UK. European Journal of Cancer. 51. S523–S523. 1 indexed citations

18.

Faust, Guy, et al.. (2010). Changes in the treatment of endometrial cancer. BJOG An International Journal of Obstetrics & Gynaecology. 117(9). 1043–1046. 1 indexed citations

19.

Boocock, David J., Guy Faust, Ketan Patel, et al.. (2007). Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent. Cancer Epidemiology Biomarkers & Prevention. 16(6). 1246–1252. 675 indexed citations breakdown →

20.

Boocock, David J., Ketan Patel, Guy Faust, et al.. (2006). Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. Journal of Chromatography B. 848(2). 182–187. 166 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact